Biotech Values

[dav1234]

Achillion Pharmaceuticals announces the resignation of its Senior VP of Clinical Development and Chief Medical Officer, Elizabeth Olek, effective June 18. Milind Deshpande, Ph.D., President of R&D and Chief Scientific Officer, will assume oversight of all ongoing and planned clinical trials. The resignation comes at a key time as the company moves into important clinical trials for its protease inhibitor, ACH-1625, and second-generation NS5A inhibitor, ACH-3102, later this year. Shares -4.2% AH